Market Research Logo

Lithuania Pharmaceuticals and Healthcare Report Q2 2016

Lithuania Pharmaceuticals and Healthcare Report Q2 2016

BMI View: Lithuania's pharmaceutical and healthcare market represents a modest prospect for investmentfrom multinational firms. Increasing demand due to a rising burden of chronic disease will translate to anincrease in sales; however, fiscal policies and the small size of the market will limit revenue earningopportunities.

Headline Expenditure Projections

Pharmaceuticals: EUR616mn (USD677mn) in 2015 to EUR638mn (USD682mn) in 2016; +3.6% inlocal currency terms and 0.7% in US dollar terms. Forecast unchanged from Q116.

Healthcare: EUR2.15bn (USD2.37bn) in 2015 to EUR2.20bn (USD2.35bn) in 2016; +2.0% in localcurrency terms and -0.8% in US dollar terms. Forecast unchanged from Q116.


BMI Industry View
Table: Headline Pharmaceuticals & Healthcare Forecasts (Lithuania 2014
2020)
SWOT
Industry Forecast
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Lithuania 2012
2020)
Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Lithuania 2012
2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Lithuania 2012
2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Lithuania 2012
2020)
Prescription Drug Market Forecast
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Lithuania 2012
2020)
Patented Drug Market Forecast
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Lithuania 2012
2020)
Generic Drug Market Forecast
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Lithuania 2012
2020)
OTC Medicine Market Forecast
Table: Over
TheCounter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Lithuania 20122020)
Pharmaceutical Trade Forecast
Table: Pharmaceutical Trade Data And Forecasts (Lithuania 2014
2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (Lithuania 2014
2020)
Industry Risk Reward Index
Central And Eastern Europe Risk/Reward Index
Lithuania Risk/Reward Index
Rewards
Risks
Regulatory Review
Intellectual Property Regime
Pricing Regime
Table: Wholesale Mark
Ups For Reimbursed And NonReimbursed Medicines
Reimbursement Regime
Table: Retail Mark
Ups For Reimbursed And NonReimbursed Medicines
Market Overview
Healthcare Sector
Table: Healthcare Resources (Lithuania 2010
2015)
Table: Healthcare Personnel (Lithuania 2010
2015)
Table: Healthcare Activity (Lithuania 2010
2015)
Research & Development
Clinical Trials
Epidemiology
Competitive Landscape
ResearchBased Industry
Table: Members of the Innovative Pharmaceutical Industry Association (IFPA)
Table: Multinational Market Activity
Generic Drugmakers
Pharmaceutical Distribution
Pharmaceutical Retail Sector
Company Profile
Valentis
Sanitas (Valeant)
Sicor Biotech (Teva)
Demographic Forecast
Table: Population Headline Indicators (Lithuania 1990
2025)
Table: Key Population Ratios (Lithuania 1990
2025)
Table: Urban/Rural Population & Life Expectancy (Lithuania 1990
2025)
Table: Population By Age Group (Lithuania 1990
2025)
Table: Population By Age Group % (Lithuania 1990
2025)
Glossary
Methodology
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Index Methodology
Index Overview
Table: Pharmaceutical Risk/Reward Index Indicators
Indicator Weightings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report